Kazimierz Groen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazimierz Groen has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Ellen van der Spek
Department of Internal Medicine Rijnstate Hospital Arnhem The Netherlands
4 shared publicationsInger S. Nijhof
Department of Internal Medicine Antonius Ziekenhuis Nieuwegein The Netherlands
4 shared publicationsGerjo A. Velders
Department of Internal Medicine Gelderse Vallei Ede The Netherlands
3 shared publicationsKazem Nasserinejad
HOVON Foundation Rotterdam The Netherlands
3 shared publicationsKoen de Heer
Department of Internal Medicine Flevoziekenhuis Almere The Netherlands
3 shared publicationsMark‐David Levin
Department of Internal Medicine Albert Schweitzer Hospital Dordrecht The Netherlands
3 shared publications
Latest Publications
- Open Access
- 8 December 2025
- Published by Wiley in HemaSphere
- Vol. 9 (12)
Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
- 8 December 2025
- Published by Wiley in HemaSphere
- Vol. 9 (12)
Open AccessUncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
- Open Access
- 5 October 2025
- Published by Wiley in HemaSphere
- Vol. 9 (10)
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first‐line therapy irrespective of frailty levels
The treatment landscape for older patients with multiple myeloma (MM) has rapidly evolved with the introduction of CD38‐targeting antibodies. Yet, outcomes remain highly variable and are only partially explained by frailty status. To address this, we investigated the impact of the immune system on survival outcomes of 89 newly diagnosed MM patients in the HOVON‐143 trial, where frail or intermediate‐fit patients received daratumumab–ixazomib–dexamethasone. Comprehensive immunophenotyping of lymphoid and myeloid subsets as relative or absolute counts in peripheral blood (PB) and bone marrow revealed comparable immune composition between frail and intermediate‐fit patients at diagnosis, except for reduced naive CD4 + and CD8 + T‐cells and increased effector memory CD4 + T‐cells and CD56 bright NK‐cells in frail patients. Among 36 T‐cell and NK‐cell subsets analyzed, 9 subsets—measured as absolute counts in PB—showed strong association with progression‐free survival (PFS) and 5 with overall survival (OS). Four subsets were linked to both PFS and OS: higher absolute counts of naive CD8 + T‐cells, CD38 + CD4 + T‐cells, and CD56 dim CD57 + NK‐cells were associated with longer survival, whereas elevated EM CD8 + T‐cell counts were linked to shorter survival. Using the most predictive immune parameters, we subsequently developed two immune risk scores—one for PFS and one for OS—which remained strongly associated with survival after adjusting for frailty status, disease stage, and cytogenetic risk. Our findings underscore the importance of a composite analysis of the immune system and demonstrate the association of baseline immune parameters with survival outcomes of first‐line therapy in non‐fit MM patients.
- 5 October 2025
- Published by Wiley in HemaSphere
- Vol. 9 (10)
Open AccessImmune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first‐line therapy irrespective of frailty levels
The treatment landscape for older patients with multiple myeloma (MM) has rapidly evolved with the introduction of CD38‐targeting antibodies. Yet, outcomes remain highly variable and are only partially explained by frailty status. To address this, we investigated the impact of the immune system on survival outcomes of 89 newly diagnosed MM patients in the HOVON‐143 trial, where frail or intermediate‐fit patients received daratumumab–ixazomib–dexamethasone. Comprehensive immunophenotyping of lymphoid and myeloid subsets as relative or absolute counts in peripheral blood (PB) and bone marrow revealed comparable immune composition between frail and intermediate‐fit patients at diagnosis, except for reduced naive CD4 + and CD8 + T‐cells and increased effector memory CD4 + T‐cells and CD56 bright NK‐cells in frail patients. Among 36 T‐cell and NK‐cell subsets analyzed, 9 subsets—measured as absolute counts in PB—showed strong association with progression‐free survival (PFS) and 5 with overall survival (OS). Four subsets were linked to both PFS and OS: higher absolute counts of naive CD8 + T‐cells, CD38 + CD4 + T‐cells, and CD56 dim CD57 + NK‐cells were associated with longer survival, whereas elevated EM CD8 + T‐cell counts were linked to shorter survival. Using the most predictive immune parameters, we subsequently developed two immune risk scores—one for PFS and one for OS—which remained strongly associated with survival after adjusting for frailty status, disease stage, and cytogenetic risk. Our findings underscore the importance of a composite analysis of the immune system and demonstrate the association of baseline immune parameters with survival outcomes of first‐line therapy in non‐fit MM patients.
- Open Access
- 24 July 2024
- Published by Wiley in HemaSphere
- Vol. 8 (7)
Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step‐up dosing
- 24 July 2024
- Published by Wiley in HemaSphere
- Vol. 8 (7)
Open AccessProphylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step‐up dosing
- Open Access
- 4 July 2024
- Published by Wiley in HemaSphere
- Vol. 8 (7)
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
- 4 July 2024
- Published by Wiley in HemaSphere
- Vol. 8 (7)
Open AccessAssessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
- Open Access
- 19 October 2023
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 180, 105264
Correctly structured problem lists lead to better and faster clinical decision-making in electronic health records compared to non-curated problem lists: A single-blinded crossover randomized controlled trial
- 19 October 2023
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 180, 105264
Open AccessCorrectly structured problem lists lead to better and faster clinical decision-making in electronic health records compared to non-curated problem lists: A single-blinded crossover randomized controlled trial
- Open Access
- 28 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 63, 102167
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
- 28 August 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 63, 102167
Open AccessIxazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial